Orphanet: Recherche simple

Rechercher un essai clinique

Autre(s) option(s) de recherche

84 Résultat(s)

Essai(s) clinique(s) national(aux)

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL Universitätsklinikum Köln Klinik I für Innere Medizin

DSHNHL 2004-3 (UNFOLDER 21/14 Study): Phase III randomized study of immunochemotherapy Rituximab-CHOP with or without radiotherapy in patients with aggressive, B-Cell Non-Hodgkin's Lymphoma Universitätsklinikum des Saarlandes Klinik für Innere Medizin I

DSHNHL 2004-2 (FLYER): Randomized Phase III Study: 6 x anti-CD20-antibody Rituximab + 6 x CHOP-21 vs. 6 x anti-CD20-antibody Rituximab + 4 x CHOP-21 in patients aged 18-60 years with aggressive CD20 positive B-Cell Lymphoma - DE Universitätsklinikum des Saarlandes Klinik für Innere Medizin I

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -AU Institution: Information not provided - AU

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

Etude randomisée en ouvert évaluant la sécurité d'emploi et l'efficacité de l'ibrutinib chez des patients enfants et jeunes adultes atteints d'un lymphome non hodgkinien à cellules B matures en rechute ou réfractaire - BE Institution: Information not provided - BE

HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U- BE UZ Leuven - Campus Gasthuisberg Department of Hematology

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -CA Institution: Information not provided - CA

BURKIMAB-14: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients - ES ICO Badalona - Hospital Germans Trias i Pujol Servicio de Hematología Clínica

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - ES Institution: Information not provided - ES

Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma -GB Institution: Information not provided - US

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -IL Institution: Information not provided - IL

(CARMEN): Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma IRCCS Ospedale San Raffaele Dipartimento di Oncologia

CARPALL: Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies GOSH NHS Foundatin Trust Great Ormond Street Hospital

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts Ospedale Regionale di Bellinzona e Valli Unità di Ricerca Clinica in Oncologia - Istituto Oncologico della Svizzera Italiana

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) -DE- Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT Universitätsklinikum der Paracelsus Medizinischen Privatuniversität Universitätsklinik für Kinder- und Jugendheilkunde

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT Medizinische Universität Graz Klinische Abteilung für pädiatrische Hämato-Onkologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT Medizinische Universität Innsbruck Pädiatrie I

BIANCA: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL) - AT Institution: Information not provided - AT

BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - AT Institution: Information not provided - AT

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT St. Anna Kinderspital Zentrum für Kinder- und Jugendheilkunde

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - NL Erasmus MC - Erasmus Medisch Centrum Polikliniek Kinderhematologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - CH Institution: Information not provided - CH

BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - CH Institution: Information not provided - CH

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - DE Universitätsklinikum Köln Klinik I für Innere Medizin

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -CA Institution: Information not provided - CA

CARBON: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies - ES Institution: Information not provided - ES

A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 (PD-1) monoclonal antibody, in Patients with B-cell Malignancies - ES Institution: Information not provided - ES

Parsaclisib Rollover study: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) - ES Institution: Information not provided - ES

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES Hospital Universitario 12 de Octubre Unidad de Ensayos Clínicos de Fase Temprana en Hematología

ROMULUS: Etude randomisée de phase II évaluant le polatuzumab vedotin ou le pinatuzumab vedotin associés au rituximab chez des patients atteints de lymphome non hodgkinien récidivant/réfractaire - FR Institution: Information not provided - FR

ELM-2 : Étude en ouvert évaluant l'activité antitumorale et la tolérance de REGN1979, un anticorps bispécifique anti-CD20 x anti-CD3, chez les patients atteints d'un lymphome non hodgkinien à cellules B récidivant ou réfractaire -FR Institution: Information not provided - FR

Étude de phase 1, évaluant le PF-05082566 en monothérapie chez des patients ayant un cancer en stade avancé, et en association avec rituximab chez des patients ayant un lymphome non hodgkinien (LNH) - FR CHU de Rennes - Hôpital Pontchaillou Service d'hématologie clinique

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - IT Institution: Information not provided - IT

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -GB Institution: Information not provided - GB

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - GB Institution: Information not provided - UK

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Deutsches Krebsforschungszentrum Klinische Kooperationseinheit Pädiatrische Onkologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Regensburg Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universitätsklinikum Würzburg

PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE Institution: Information not provided - DE

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Charité - Universitätsmedizin Berlin

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies Universitätsklinikum Essen Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universitätsklinikum Münster

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE Universität Leipzig

UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES Institution: Information not provided - ES

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES Institution: Information not provided - ES

Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques CLCC Institut Gustave Roussy Département d'hématologie

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR CLCC Institut Paoli Calmettes Institut Paoli-Calmettes

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders Institution: Information not provided - IT

A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy IRCCS Istituto Clinico Humanitas U.O. Oncologia Medica ed Ematologia

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette S.C. di Ematologia

UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB Addenbrooke's Hospital Cambridge Cancer Trials Centre

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB GOSH NHS Foundatin Trust Great Ormond Street Hospital

UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies Guy's Hospital Department of Haematology

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies GlaxoSmithKline

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH Ospedale Regionale di Bellinzona e Valli

STEP: Programme d'extension à long terme du Sorafénib - BE Cliniques universitaires Saint-Luc - UCLouvain Pneumologie_Oncologie thoracique

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO U.O. di Oncoematologia

Essai(s) clinique(s) multinational(aux)

Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Institution: Information not provided - US

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Institution: Information not provided - US

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia Erasmus MC - Erasmus Medisch Centrum

A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies Sanofi-aventis Groupe

An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphomas Ergomed Clinical Research Limited

A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies Institution: Information not provided - US

SELINDA: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP Institution: Information not provided - US

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL Institution: Information not provided - US

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Institution: Information not provided - US

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination) Hoffmann-La Roche Hoffmann - La Roche Ltd.

A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination) PharmaMar S.A. Pharma Mar S.A.

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL) Celgene Corporation

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders Bellicum Pharmaceuticals, Inc.

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas Institution: Information not provided - US

APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination) PharmaMar S.A. Pharma Mar S.A.

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL
Universitätsklinikum Köln

Klinik I für Innere Medizin

DSHNHL 2004-3 (UNFOLDER 21/14 Study): Phase III randomized study of immunochemotherapy Rituximab-CHOP with or without radiotherapy in patients with aggressive, B-Cell Non-Hodgkin's Lymphoma
Universitätsklinikum des Saarlandes

Klinik für Innere Medizin I

DSHNHL 2004-2 (FLYER): Randomized Phase III Study: 6 x anti-CD20-antibody Rituximab + 6 x CHOP-21 vs. 6 x anti-CD20-antibody Rituximab + 4 x CHOP-21 in patients aged 18-60 years with aggressive CD20 positive B-Cell Lymphoma - DE
Universitätsklinikum des Saarlandes

Klinik für Innere Medizin I

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -AU
Institution: Information not provided - AU

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

Etude randomisée en ouvert évaluant la sécurité d'emploi et l'efficacité de l'ibrutinib chez des patients enfants et jeunes adultes atteints d'un lymphome non hodgkinien à cellules B matures en rechute ou réfractaire - BE
Institution: Information not provided - BE

HOVON 130 NHL: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U- BE
UZ Leuven - Campus Gasthuisberg

Department of Hematology

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -CA
Institution: Information not provided - CA

BURKIMAB-14: Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients - ES
ICO Badalona - Hospital Germans Trias i Pujol

Servicio de Hematología Clínica

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - ES
Institution: Information not provided - ES

Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - US

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms -IL
Institution: Information not provided - IL

(CARMEN): Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma
IRCCS Ospedale San Raffaele

Dipartimento di Oncologia

CARPALL: Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
GOSH NHS Foundatin Trust

Great Ormond Street Hospital

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Ospedale Regionale di Bellinzona e Valli

Unità di Ricerca Clinica in Oncologia - Istituto Oncologico della Svizzera Italiana

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) -DE-
Universitätsklinikum Münster

Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

Universitätsklinik für Kinder- und Jugendheilkunde

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Medizinische Universität Graz

Klinische Abteilung für pädiatrische Hämato-Onkologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
Medizinische Universität Innsbruck

Pädiatrie I

BIANCA: A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL) - AT
Institution: Information not provided - AT

BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - AT
Institution: Information not provided - AT

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - AT
St. Anna Kinderspital

Zentrum für Kinder- und Jugendheilkunde

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia - NL
Erasmus MC - Erasmus Medisch Centrum

Polikliniek Kinderhematologie

B-NHL 2013: Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (Phase 3) - CH
Institution: Information not provided - CH

BELINDA: Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial - CH
Institution: Information not provided - CH

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - DE
Universitätsklinikum Köln

Klinik I für Innere Medizin

A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART19.1 in Patients With Relapsed or Refractory CD19 Positive B Cell Malignancies
Universitätsklinikum Münster

Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -CA
Institution: Information not provided - CA

CARBON: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies - ES
Institution: Information not provided - ES

A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 (PD-1) monoclonal antibody, in Patients with B-cell Malignancies - ES
Institution: Information not provided - ES

Parsaclisib Rollover study: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) - ES
Institution: Information not provided - ES

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies - ES
Hospital Universitario 12 de Octubre

Unidad de Ensayos Clínicos de Fase Temprana en Hematología

ROMULUS: Etude randomisée de phase II évaluant le polatuzumab vedotin ou le pinatuzumab vedotin associés au rituximab chez des patients atteints de lymphome non hodgkinien récidivant/réfractaire - FR
Institution: Information not provided - FR

ELM-2 : Étude en ouvert évaluant l'activité antitumorale et la tolérance de REGN1979, un anticorps bispécifique anti-CD20 x anti-CD3, chez les patients atteints d'un lymphome non hodgkinien à cellules B récidivant ou réfractaire -FR
Institution: Information not provided - FR

Étude de phase 1, évaluant le PF-05082566 en monothérapie chez des patients ayant un cancer en stade avancé, et en association avec rituximab chez des patients ayant un lymphome non hodgkinien (LNH) - FR
CHU de Rennes - Hôpital Pontchaillou

Service d'hématologie clinique

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - IT
Institution: Information not provided - IT

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma -GB
Institution: Information not provided - GB

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies - GB
Institution: Information not provided - UK

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum

Klinische Kooperationseinheit Pädiatrische Onkologie

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg

Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg

PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin

INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen

Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universität Leipzig

UNITY: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin' s Lymphoma - ES
Institution: Information not provided - ES

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) - ES
Institution: Information not provided - ES

Étude de phase I/II d'escalade de dose de l'inhibiteur d'Histone déacétylase S 78454 administré par voie orale dans la maladie de Hodgkin, les Lymphomes malins non-Hodgkiniens, et les Leucémies Lymphoïdes Chroniques
CLCC Institut Gustave Roussy

Département d'hématologie

A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes

Institut Paoli-Calmettes

Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders
Institution: Information not provided - IT

A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy
IRCCS Istituto Clinico Humanitas

U.O. Oncologia Medica ed Ematologia

Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette

S.C. di Ematologia

UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital

Cambridge Cancer Trials Centre

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust

Great Ormond Street Hospital

UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital

Department of Haematology

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies
GlaxoSmithKline

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli

STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain

Pneumologie_Oncologie thoracique

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO

U.O. di Oncoematologia

Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Institution: Information not provided - US

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms
Institution: Information not provided - US

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Erasmus MC - Erasmus Medisch Centrum

A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies
Sanofi-aventis Groupe

An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphomas
Ergomed Clinical Research Limited

A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Institution: Information not provided - US

SELINDA: A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
Institution: Information not provided - US

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
Institution: Information not provided - US

ELM-2: An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Institution: Information not provided - US

An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche

Hoffmann - La Roche Ltd.

A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (coordination)
PharmaMar S.A.

Pharma Mar S.A.

A Phase 1, Multi-center, Open-label, Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R iNHL)
Celgene Corporation

CaspaCide TCR α β haplo HSCT: Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.

A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US

APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)
PharmaMar S.A.

Pharma Mar S.A.